September 13, 2019
Chugai Pharmaceutical’s investigational humanized recycling anti-IL-6 receptor monoclonal antibody satralizumab, code name SA237, hit the primary target in a PIII multinational trial evaluating the agent as a monotherapy in patients with neuromyelitis optica spectrum disorder (NMOSD), it said on September...read more